A Skeptical Look at Aducanumab

The big news in Alzheimer disease (AD) is the Federal Drug Administration’s approval of aducanumab. It is the first-ever disease-modifying AD treatment, which works by targeting amyloid beta plaques in the brain.

But its approval has also generated controversy. Three members of the Federal Drug Administration’s advisory committee have resigned, arguing that evidence for the drug’s efficacy was not strong enough to merit approval.

George Perry, PhD, is among the skeptics. In this Mental Health Minute, he raises questions about the drug’s mechanism. He has long been skeptical of what he calls the amyloid hypothesis, and has searched for alternative explanations.

Dr Perry is the Semmes Foundation Distinguished University Chair in Neurobiology at the University of Texas, San Antonio.

Do you think aducanumab will be safe and effective for your patients? Share comments with your colleagues by emailing PTEditor@mmhgroup.com. Comments may be shared online pending review and editing for style.